Each tablet contains Risperidone 1 mg, 2 mg, 3 mg, or 4 mg.

Rispond Tablets contain Risperidone, an atypical antipsychotic indicated for the treatment of schizophrenia and acute manic episodes associated with bipolar disorder. By modulating both dopaminergic and serotonergic neurotransmission, Risperidone effectively reduces positive and negative symptoms of schizophrenia while improving mood stability in bipolar disorder. It offers a favorable efficacy profile with a lower incidence of extrapyramidal symptoms compared to conventional antipsychotic agents when used at recommended doses.

Rispond Tablets are indicated for the treatment and management of schizophrenia and acute manic or mixed episodes associated with Bipolar I Disorder. They may also be used in other psychiatric conditions as directed by the treating physician.

Risperidone is an atypical antipsychotic that exerts its therapeutic effects primarily through potent antagonism of dopamine D2 and serotonin 5-HT2A receptors in the central nervous system. This dual receptor blockade helps reduce psychotic symptoms, improve mood, and lower the risk of extrapyramidal adverse effects compared with conventional antipsychotics. (Note: The reference text appears to include Trihexyphenidyl in the pharmacodynamics section; however, Rispond contains only Risperidone, so the pharmacodynamics has been appropriately described for Risperidone alone.)

For adults with schizophrenia, treatment is generally initiated with 2 mg once daily, with dose adjustments of 1–2 mg per day to achieve a usual maintenance dose of 4–8 mg daily. For children and adolescents (10–17 years) with bipolar mania, therapy is initiated with 0.5 mg once daily, with gradual titration by 0.5–1 mg daily to a target dose of approximately 2.5 mg daily, or as directed by the physician.

Rispond Tablets are contraindicated in patients with known hypersensitivity to Risperidone or any component of the formulation. The provided prescribing information also lists narrow-angle glaucoma as a contraindication.